The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application.
Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for JITC, an outlet devoted to and created by today's leaders in the field.
Read the Journal for ImmunoTherapy of Cancer (JITC)
As of Jan. 1, 2020, JITC transitioned to a new publishing relationship with BMJ. The journal’s new publication home, complete with JITC’s fully-searchable article archive, is jitc.bmj.com. Read more about this exciting change in the editorial announcement from JITC’s Editor-in-Chief Dr. Pedro J. Romero.
JITC is launching two new sections in 2020 and is now collecting submissions for peer review. Read more about these sections, "Immune Cell Therapies and Immune Cell Engineering" and "Oncolytic and Local Immunotherapy," and submit today!
Pedro J. Romero, MD, JITC Editor-in-Chief, welcomes applications from interested individuals who would like to take advantage of the many benefits of serving as a JITC manuscript reviewer. Benefits include:
The Journal for ImmunoTherapy of Cancer (JITC) increased its impact factor to 8.728 in 2019. JITC’s impact factor places JITC in the top 3 percent of all fully open access oncology journals and ranks it in the top 8 percent of all journals published in the categories of oncology and immunology.
Published in the annual Journal Citation Reports (JCR), the latest JITC impact factor is a calculation determined on the number of 2018 citations accumulated for JITC manuscripts published in 2016 and 2017. Other journal metrics for JITC may be found on the journal website.
As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC will provide members with a 50 percent discount on processing fees for all JITC articles submitted and accepted in 2020.
For questions regarding the discount that would be verified and applied upon post-review acceptance, please contact JITCEditor@sitcancer.org or (414) 271-2456.
Indicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention picked up for a research output. Learn more here.
Developing the ability to use tumor-directed therapies to trigger potentially therapeutic immune responses against cancer antigens remains a high priority for cancer immunotherapy. We hypothesized that histotripsy, a novel non-invasive, non-thermal ablation modality that uses ultrasound-generated acoustic cavitation to disrupt tissues, could engender adaptive immune responses to tumor antigens.
Quality measures are important because they can help improve and standardize the delivery of cancer care among healthcare providers and across tumor types. In an environment characterized by a rapidly shifting immunotherapeutic landscape and lack of associated long-term outcome data, defining quality measures for cancer immunotherapy is a high priority yet fraught with many challenges.
I was invited to make you aware of this publication when it was finished, and now it is. It is an unusually large book which has phenomenal photographsfrom Mascagni's original work - still the best way to see the lymphatic system. Enjoy!
Thought the following blog would be of interest to this audience/society. https://www.immuno-oncologyresearchtrends.com/home/2020/3/22/true-costs-and-risks-of-covid-19-for-immuno-therapy-patients It discusses costs for cancer patients, R&D, CART ...
Good ------Original Message------ An online system is being used with a new curation method to assemble and describe all publications related to COVID 19. Core descriptions of articles are done with a primary and secondary review. From these ...
An online system is being used with a new curation method to assemble and describe all publications related to COVID 19. Core descriptions of articles are done with a primary and secondary review. From these neatly described articles, key issues are ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org